Antiangiogenic drugs and tyrosine kinases

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer vascularization involves diverse strategies like neoangiogenesis, vasculogenesis, and vessel cooption.
• Understanding these mechanisms is crucial for developing effective antivascular therapies.
• Tumor-induced neoangiogenesis is the most understood, leading to the development of early antiangiogenic drugs.

Purpose of the Study:

• To review current knowledge on cancer vascularization mechanisms and identify drugable targets.
• To summarize antiangiogenic approaches, focusing on tyrosine kinase inhibitors (TKIs).
• To discuss preclinical and clinical applications of TKIs and future perspectives.

Main Methods:

• Literature review of cancer vascularization strategies and molecular mechanisms.
• Analysis of growth factor receptors, particularly tyrosine kinases, as therapeutic targets.
• Overview of preclinical studies and clinical data for antiangiogenic TKIs.

Main Results:

• Several cancer vascularization strategies are identified, with varying degrees of understanding.
• Tyrosine kinases (e.g., KIT, VEGFRs, EGFR) are key targets for antiangiogenic therapy.
• Clinically available TKIs show promise, but novel inhibitors and strategy-specific designs are needed.

Conclusions:

• Targeting cancer vascularization, especially neoangiogenesis via TKIs, is a validated therapeutic approach.
• Further advancements require identifying new kinase targets and developing therapies tailored to specific vascularization strategies.
• Personalized antivascular therapies hold promise for improved cancer treatment outcomes.